ReviewFrontiers in oncology2026
Multimodal AI fusion: integrating MRI with PET/CT, histopathology, and liquid biopsy for bone tumor diagnosis.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis of bone tumors, though a low-incidence occurrence, presents a formidable challenge due to the morphological heterogeneity and variable biological behavior of these lesions. No single diagnostic modality whether imaging or biopsy is sufficient to provide the comprehensive information necessary for definitive diagnosis, accurate staging, and effective treatment planning. This report argues that a fragmented, sequential approach to diagnosis is inherently limited and that the future of orthopedic oncology lies in the integration of diverse data streams. Multimodal artificial intelligence (AI) offers a promising supportive approach by creating an AI-enabled integrative decision-support environment where computational systems can synthesize and contextualize information from magnetic resonance imaging (MRI), positron emission tomography computed tomography (PET/CT), histopathology, and liquid biopsy. This report details the specific capabilities and limitations of each of these foundational modalities, outlines the technical architectures required for their fusion, and illustrates how an integrated AI system can augment clinical workflows. It also addresses the critical challenges that must be overcome for clinical adoption, including data standardization, algorithmic interpretability, and economic viability, ultimately positioning this approach as an important emerging direction for future precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.